4//SEC Filing
D'Angio Paul 4
Accession 0001209191-21-012359
CIK 0001538210other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:23 PM ET
Size
14.6 KB
Accession
0001209191-21-012359
Insider Transaction Report
Form 4
NexImmune, Inc.NEXI
D'Angio Paul
Director
Transactions
- Conversion
Common Stock
2021-02-17+19,627→ 19,627 total - Conversion
Common Stock
2021-02-17+4,110→ 23,737 total - Conversion
Common Stock
2021-02-17+4,110→ 27,847 total - Conversion
Series A Preferred Stock
2021-02-17−19,627→ 0 total→ Common Stock (19,627 underlying) - Conversion
Series A2 Preferred Stock
2021-02-17−4,110→ 0 total→ Common Stock (4,110 underlying) - Conversion
Series A3 Preferred Stock
2021-02-17−4,110→ 0 total→ Common Stock (4,110 underlying)
Footnotes (3)
- [F1]The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.
- [F2]The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
- [F3]Not applicable.
Documents
Issuer
NexImmune, Inc.
CIK 0001538210
Entity typeother
Related Parties
1- filerCIK 0001843748
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 4:23 PM ET
- Size
- 14.6 KB